The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of ...

Seattle biotech startup Rhizome Research has emerged from stealth with technology for creating small-molecule drug candidates ...

Alex Zhavoronkov, Founder and CEO of generative-AI drug discovery firm Insilico Medicine, discusses the company's plans after ...

The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

A Seattle-area startup called Pauling.AI is harnessing artificial intelligence to automate the early steps that lead to the discovery of new drugs.

After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...

Chai Discovery, an artificial intelligence drug-discovery company backed by OpenAI, has raised $130 million to build a “computer-aided design suite” for molecules.

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In an era where artificial intelligence (AI) is transforming ...

The Forum on Drug Discovery, Development, and Translation provides a neutral platform for dialogue and collaboration among thought leaders in government, industry, academia, consortia, foundations, ...

Pre-clinical drug discovery lies at the intersection of many disciplines in the life sciences and showcases how advancements in these fields can contribute directly to the betterment of human lives.